Yamamoto T, Suzuki K, Kishimoto A
Jpn J Antibiot. 1985 Sep;38(9):2509-14.
A newly developed human immunoglobulin preparation for intravenous use, SM-4300, has been studied in Nagoyashi-Koseiin Geriatric Hospital on the effects of 14 cases of the various severe infections in the combined use with antibiotics. The following results were obtained: The patients had many kinds of underlying diseases. Cerebral vascular disease was the most frequent underlying disease, and found in 70% of 14 patients, followed by heart failure. Among them 8 cases were chosen for the clinical evaluation by doctors in charge. SM-4300 effected good in 1 case, fairly 3 and poorly 4. The efficacy rate was summarized as 12.5%. In all cases, there were no significant side effects regarding symptoms, hematological analysis, renal and live functions. Based on these results, SM-4300 may be safe and a drug worth to try in treatment of severe infections.
一种新研发的静脉用人免疫球蛋白制剂SM - 4300,已在名古屋市小星医院针对14例各种严重感染患者联合使用抗生素时的效果进行了研究。获得了以下结果:患者患有多种基础疾病。脑血管疾病是最常见的基础疾病,在14例患者中有70%存在,其次是心力衰竭。其中8例由主管医生进行临床评估。SM - 4300治疗效果良好的有1例,尚可的有3例,不佳的有4例。有效率总计为12.5%。在所有病例中,在症状、血液学分析、肾功能和肝功能方面均未出现明显副作用。基于这些结果,SM - 4300可能是安全的,且是一种值得尝试用于治疗严重感染的药物。